418 related articles for article (PubMed ID: 32906729)
21. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
[TBL] [Abstract][Full Text] [Related]
23. Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
Silva VL; Saxena J; Nicolini F; Hoare JI; Metcalf S; Martin SA; Lockley M
Cell Death Dis; 2021 Apr; 12(4):395. PubMed ID: 33854036
[TBL] [Abstract][Full Text] [Related]
24. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
25. Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Guo Q; Lu L; Liao Y; Wang X; Zhang Y; Liu Y; Huang S; Sun H; Li Z; Zhao L
Cell Death Dis; 2018 Jan; 8(1):e3178. PubMed ID: 29324735
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Han X; Chen H; Zhou J; Steed H; Postovit LM; Fu Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30049957
[TBL] [Abstract][Full Text] [Related]
27. ONC201 induces the unfolded protein response (UPR) in high- and low-grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity.
Rumman M; Buck S; Polin L; Dzinic S; Boerner J; Winer IS
Cancer Med; 2021 May; 10(10):3373-3387. PubMed ID: 33932119
[TBL] [Abstract][Full Text] [Related]
28. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
29. COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.
Zhou Z; Jin L; Shen J; Shi W; Xu Y; Ye L; Liu J; Pan J
Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 55(1):34-42. PubMed ID: 36647720
[TBL] [Abstract][Full Text] [Related]
30. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
[TBL] [Abstract][Full Text] [Related]
31. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
32. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
33. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP; Palle K
Oncogene; 2017 Nov; 36(48):6680-6690. PubMed ID: 28806395
[TBL] [Abstract][Full Text] [Related]
34. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
[TBL] [Abstract][Full Text] [Related]
35. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
36. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
37. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells.
Gupta N; Xu Z; El-Sehemy A; Steed H; Fu Y
Gynecol Oncol; 2013 Jul; 130(1):200-6. PubMed ID: 23542683
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner L; Guan Y; Firestein R; Xiao Y; Choi Y; Rabe C; Lu S; Fuentes E; Huw LY; Lackner MR; Fu L; Amler LC; Bais C; Wang Y
Clin Cancer Res; 2015 Jul; 21(13):2941-51. PubMed ID: 25838397
[TBL] [Abstract][Full Text] [Related]
39. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
40. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
